ISPOR - POSA133 Cost-Effectiveness of Dapagliflozin for the Treatment of Heart Failure with Reduced Ejection Fraction: Analyses from the Perspectives of France and the United States

POSA133 Cost-Effectiveness of Dapagliflozin for the Treatment of Heart Failure with Reduced Ejection Fraction: Analyses from the Perspectives of France and the United States

Abstract

Authors

R Binnie AJ Omar Alsaleh

Full Text Cite This Article

Back to ISPOR Europe 2021 Abstracts: Emerging Frontiers and Opportunities

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now